RenovoRx 将来の成長

Future 基準チェック /56

RenovoRxは、70.9%と77.9%でそれぞれ年率70.9%で利益と収益が成長すると予測される一方、EPSはgrowで70.8%年率。

主要情報

70.9%

収益成長率

70.8%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	77.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqCM:RNXT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	14	-6	N/A	N/A	2
12/31/2025	0	-12	N/A	-9	3
12/31/2024	N/A	-9	N/A	-10	3
9/30/2024	N/A	-9	-9	-9	N/A
6/30/2024	N/A	-8	-9	-9	N/A
3/31/2024	N/A	-8	-10	-10	N/A
12/31/2023	N/A	-10	-10	-10	N/A
9/30/2023	N/A	-9	-10	-10	N/A
6/30/2023	N/A	-10	-10	-10	N/A
3/31/2023	N/A	-10	-9	-9	N/A
12/31/2022	N/A	-10	-9	-9	N/A
9/30/2022	N/A	-10	-10	-10	N/A
6/30/2022	N/A	-9	-8	-8	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-6	-6	-6	N/A
9/30/2021	N/A	-5	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-4	-3	-3	N/A
12/31/2020	N/A	-4	-4	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RNXTは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: RNXT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: RNXT今後 3 年以内に収益を上げることが予想されます。

収益対市場: RNXTの収益 ( 77.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: RNXTの収益 ( 77.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RNXTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

RenovoRx 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target decreased by 23% to US$8.50

Price target increased by 15% to US$11.50

Price target decreased to US$10.00

Recent updates

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx, Inc.'s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx, Inc. Announces Publication of Positive Early-Stage Clinical Data Relating to its Trans-Arterial Micro-Perfusion Therapy Platform

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

RenovoRx, Inc. Announces Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential

RenovoRx, Inc., Annual General Meeting, Jun 06, 2024

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx, Inc. announced that it has received $11.136652 million in funding

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee

Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer

RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

Renovorx Appoints Michel Ducreux as Scientific Advisory Board

Price target decreased by 23% to US$8.50

RenovoRx Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

RenovoRx, Inc. announced delayed 10-Q filing

RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board

Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial

RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

Price target increased by 15% to US$11.50

Renovorx, Inc. Announces Initial Results from A Pharmacokinetic (PK) Substudy Within the Phase III Un-Blinded Randomized Control Tiger-Pac Clinical Trial

Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

Price target decreased to US$10.00

RenovoRx, Inc. Appoints Angela Gill Nelms as Chief Operating Officer

RenovoRx reports Q2 results

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

Renovorx Appoints James Ahlers as Chief Financial Officer

RenovoRx names new finance CFO

Renovorx Launches "The Renovorx Story" Video Series

RenovoRx, Inc., Annual General Meeting, Jun 09, 2022

RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing Tiger-Pac Phase 3 Clinical Trial

We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

RenovoRx, Inc. Receives New 510(k) Clearance for its RenovoCath Delivery System Designed for Targeted Treatment of Solid Tumors

RenovoRx, Inc. has completed an IPO in the amount of $16.65 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘